Human Anti-AOC3 Recombinant Antibody (clone BTT-1002) (CAT#: NS-099CN)

Figure 1 The results of VAP-1 binding activity of the chimeric antibodies.

The binding of the chimeric antibodies and an irrelevant control antibody (ctrAb) to Ax cells expressing human VAP-1 or mock control cells was analysed by flow cytometry. Results are expressed as percentage of maximal mean channel fluorescence (MCF);

Figure 2 The inhibition of the lymphocyte binding by anti-VAP-1 antibodies.

The abilities of the murine and chimeric antibodies to block the binding of lymphocytes to HEV were analysed using an in vitro frozen section assay. Sections were treated with anti-VAP-1 antibodies or with negative control antibodies (irrelevant monoclonal antibody 3G6 or human immunoglobulin). Results of two experiments are presented with their standard errors.

Figure 3 The results of flow cytometric analysis of antibody binding to human Fcj/RI.

B2KA cells expressing human FcγR\ on their surface were incubated with the mouse (A) and chimeric (B) anti-VAP-1 antibodies followed by appropriate detection reagents. A human lgG1 antibody was used as a positive control in B.

Figure 4 The serum concentrations after i.v. injection of chimeric anti-VAP-1 antibody, BTT-1002 (panel A) and murine anti-VAP-1 antibody (panel B);

Figure 5 The clinical score of BTT-1002 treated (panel A) and placebo treated (panel B) animals.

Figure 6 The survival of rhesus monkeys in the CIA study.